Trial Profile
A randomized, double blind, active control, flexible dose, multicenter study to evaluate galantamine HBr [hydrogen bromide] in the treatment of Alzheimer's disease:Safety and effectiveness of an immediate-release table formulation.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 24 Apr 2013
Price :
$35
*
At a glance
- Drugs Galantamine (Primary) ; Donepezil
- Indications Alzheimer's disease
- Focus Therapeutic Use
- Sponsors Xian-Janssen
- 10 Sep 2011 Primary endpoint 'Alzheimer's-Disease-Assessment-Scale-cognitive-subpart' has been met.
- 10 Sep 2011 Results presented at the 15th Congress of the European Federation of Neurological Societies.
- 10 Sep 2011 Actual patient number changed as reported at the 15th Congress of the European Federation of Neurological Societies.